These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37639050)

  • 41. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.
    Lippert E; Boissinot M; Kralovics R; Girodon F; Dobo I; Praloran V; Boiret-Dupré N; Skoda RC; Hermouet S
    Blood; 2006 Sep; 108(6):1865-7. PubMed ID: 16728702
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polycythemia vera and the Jak2(V617F) mutation in a case of hereditary spherocytosis.
    Fleischman RA
    Am J Med Sci; 2013 Oct; 346(4):328-30. PubMed ID: 23588264
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
    Guru SA; Sumi MP; Mir R; Waza AA; Bhat MA; Zuberi M; Lali P; Saxena A
    Hum Cell; 2020 Oct; 33(4):1099-1111. PubMed ID: 32430672
    [TBL] [Abstract][Full Text] [Related]  

  • 44. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.
    Staerk J; Kallin A; Demoulin JB; Vainchenker W; Constantinescu SN
    J Biol Chem; 2005 Dec; 280(51):41893-9. PubMed ID: 16239216
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Convergent mechanisms of somatic mutations in polycythemia vera.
    Wang K; Swierczek S; Hickman K; Hakonarson H; Prchal JT
    Discov Med; 2011 Jul; 12(62):25-32. PubMed ID: 21794206
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.
    Pietra D; Li S; Brisci A; Passamonti F; Rumi E; Theocharides A; Ferrari M; Gisslinger H; Kralovics R; Cremonesi L; Skoda R; Cazzola M
    Blood; 2008 Feb; 111(3):1686-9. PubMed ID: 17984312
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.
    Chatambudza M; Skhosana L; Ketseoglou I; Wiggill T
    Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758219
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.
    Moliterno AR; Williams DM; Rogers O; Isaacs MA; Spivak JL
    Exp Hematol; 2008 Nov; 36(11):1480-6. PubMed ID: 18723264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.
    Ohyashiki JH; Yoneta M; Hisatomi H; Iwabuchi T; Umezu T; Ohyashiki K
    BMC Med Genet; 2012 Jan; 13():6. PubMed ID: 22251709
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
    Ha JS; Kim YK; Jung SI; Jung HR; Chung IS
    Ann Lab Med; 2012 Nov; 32(6):385-91. PubMed ID: 23130336
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].
    Chae H; Lee JH; Lim J; Jung SW; Kim M; Kim Y; Han K; Cho BS; Cho SG; Lee JW; Min WS
    Korean J Lab Med; 2009 Jun; 29(3):243-8. PubMed ID: 19571623
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
    Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
    Hexner E; Roboz G; Hoffman R; Luger S; Mascarenhas J; Carroll M; Clementi R; Bensen-Kennedy D; Moliterno A
    Br J Haematol; 2014 Jan; 164(1):83-93. PubMed ID: 24903629
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
    Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
    Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activation loop tyrosines allow the JAK2(V617F) mutant to attain hyperactivation.
    Kundrapu K; Colenberg L; Duhé RJ
    Cell Biochem Biophys; 2008; 52(2):103-12. PubMed ID: 18841497
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CRISPR/Cas9 mediated CXCL4 knockout in human iPS cells of polycythemia vera patient with JAK2 V617F mutation.
    Boehnke J; Atakhanov S; Toledo MAS; Schüler HM; Sontag S; Chatain N; Koschmieder S; Brümmendorf TH; Kramann R; Zenke M
    Stem Cell Res; 2021 Aug; 55():102490. PubMed ID: 34391098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children.
    Ismael O; Shimada A; Hama A; Sakaguchi H; Doisaki S; Muramatsu H; Yoshida N; Ito M; Takahashi Y; Akita N; Sunami S; Ohtsuka Y; Asada Y; Fujisaki H; Kojima S
    Pediatr Blood Cancer; 2012 Sep; 59(3):530-5. PubMed ID: 22106054
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.
    Ishii T; Bruno E; Hoffman R; Xu M
    Blood; 2006 Nov; 108(9):3128-34. PubMed ID: 16757685
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Detection of Exon 12 and 14 Mutations in Janus Kinase 2 Gene Including a Novel Mutant in V617F Negative Polycythemia Vera Patients from Pakistan.
    Akram AM; Kausar H; Chaudhary A; Khalid AM; Shahzad MM; Akhtar MW; Sabar MF; Sajid N; Anazi NA; Aleem A; Iqbal Z
    J Cancer; 2018; 9(23):4341-4345. PubMed ID: 30519338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.